Methods and compositions for modulating serum cortisol levels
    1.
    发明申请
    Methods and compositions for modulating serum cortisol levels 审中-公开
    调节血清皮质醇水平的方法和组合物

    公开(公告)号:US20060194815A1

    公开(公告)日:2006-08-31

    申请号:US11293866

    申请日:2005-12-02

    IPC分类号: A61K31/496

    摘要: The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome.

    摘要翻译: 本发明涉及皮质醇调节化合物,包括但不限于苯甲酰胺和苯甲酸衍生物如普鲁卡因和普鲁卡因衍生物,用于治疗皮质醇介导的病症的组合物和方法,包括但不限于与年龄有关的抑郁症,高血压 ,阿尔茨海默病和获得性免疫缺陷综合征。

    NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS
    2.
    发明申请
    NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS 审中-公开
    神经保护性苯甲酸和苯甲酸酯化合物

    公开(公告)号:US20090286876A1

    公开(公告)日:2009-11-19

    申请号:US12269559

    申请日:2008-11-12

    摘要: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明提供在哺乳动物(例如人)中治疗至少一种神经障碍或疾病如阿尔茨海默病的症状的治疗方法,其中涉及哺乳动物细胞中β淀粉样肽和/或谷氨酸的病原体的毒性 并且期望抑制随后诱导的病理学途径,包括向需要这种治疗的哺乳动物施用有效量的N-芳基酰胺或(N-氨基烷基)苯甲酰胺,包括其药学上可接受的盐。

    Benzamide compounds
    3.
    发明申请
    Benzamide compounds 审中-公开
    苯甲酰胺化合物

    公开(公告)号:US20060194814A1

    公开(公告)日:2006-08-31

    申请号:US11292797

    申请日:2005-12-02

    IPC分类号: A61K31/496

    CPC分类号: A61K31/496

    摘要: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明提供了预防或治疗哺乳动物(例如人)中的病理状况或症状的治疗方法,其中牵涉到病原体如逆转录病毒对哺乳动物细胞的感染性,并且希望抑制其感染性,包括给予 需要这种治疗的哺乳动物,有效量的抑制病原性感染性的氨基酸的哌嗪基酰胺的N-苯甲酰胺衍生物,包括其药学上可接受的盐。 本发明还提供了用于预防或治疗哺乳动物(例如人)的神经病理学病症或症状的治疗方法,其包括对需要这种治疗的哺乳动物施用有效量的哌嗪基酰胺的N-苯甲酰胺衍生物 其氨基酸,包括其药学上可接受的盐。

    Sigma-1 receptor ligand with acetylcholinesterase
    4.
    发明申请
    Sigma-1 receptor ligand with acetylcholinesterase 审中-公开
    具有乙酰胆碱酯酶的Sigma-1受体配体

    公开(公告)号:US20060247248A1

    公开(公告)日:2006-11-02

    申请号:US11347020

    申请日:2006-02-03

    IPC分类号: A61K31/495 C07D241/04

    摘要: A novel compound and method for preventing or treating neurodegenerative diseases by inhibiting acetylcholinesterase and binding the sigma-1 receptor are disclosed. Dimethylcarbamic acid 2,3-bis-dimethylcarbamoyloxy-6-[4-(4-ethyl-piperazin-yl)-butyryl]-phenyl ester and its derivatives represent a novel therapeutic strategy against β-amyloid peptide induced neurotoxicity, in inhibiting acetylcholinesterase, in improving cholinergic transmission, in binding the sigma-1 receptor, and in releasing a metabolite that is active both as a sigma-1 receptor ligand and an antioxidant.

    摘要翻译: 公开了通过抑制乙酰胆碱酯酶和结合σ-1受体来预防或治疗神经变性疾病的新型化合物和方法。 二甲基氨基甲酸2,3-双 - 二甲基氨基甲酰氧基-6- [4-(4-乙基 - 哌嗪基) - 丁酰基] - 苯酯及其衍生物代表了β-淀粉样肽诱导的神经毒性的新型治疗策略,用于抑制乙酰胆碱酯酶, 改善胆碱能传递,结合σ-1受体,以及释放作为σ-1受体配体和抗氧化剂有活性的代谢物。

    Neuroprotective spirostenol pharmaceutical compositions
    5.
    发明申请
    Neuroprotective spirostenol pharmaceutical compositions 审中-公开
    神经保护螺螺甾醇药物组合物

    公开(公告)号:US20060009433A1

    公开(公告)日:2006-01-12

    申请号:US11031538

    申请日:2005-01-07

    IPC分类号: A61K31/58

    CPC分类号: A61K31/58

    摘要: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with a neurodegenerative disorder such as neurotoxicity or a neuropathology in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The invention further provides a method for inducing stem cell differentiation into neuronal cells, by administering to the patient a therapeutically effective amount of a compound of the invention.

    摘要翻译: 本发明涉及用于治疗,预防或降低发生与神经变性疾病相关的病症或疾病或与神经变性疾病如神经毒性或神经病理学相关的症状的风险的方法,试剂盒,组合和组合物,特别是 β-淀粉样蛋白诱导的神经毒性和阿尔茨海默病。 本发明还提供了通过向患者施用治疗有效量的本发明化合物来诱导干细胞分化成神经细胞的方法。

    Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
    6.
    发明申请
    Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease 审中-公开
    (4-烷基哌嗪基)(苯基)甲酮在治疗阿尔茨海默病中的应用

    公开(公告)号:US20090197891A1

    公开(公告)日:2009-08-06

    申请号:US10599952

    申请日:2005-04-12

    IPC分类号: A61K31/495 C12N5/06

    CPC分类号: C07D295/192 A61K31/495

    摘要: The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明提供了治疗哺乳动物(例如人)中的阿尔茨海默病的至少一种症状的治疗方法,其中涉及β淀粉样蛋白肽哺乳动物细胞的病原体的毒性,并期望抑制随后诱导的病理学途径,包括 对需要这种治疗的哺乳动物施用有效量的苯甲酰基哌嗪衍生物,包括其药学上可接受的盐。

    Anti-Hiv Quinuclidine Compounds
    8.
    发明申请
    Anti-Hiv Quinuclidine Compounds 审中-公开
    抗-Hiv奎宁环化合物

    公开(公告)号:US20080194619A1

    公开(公告)日:2008-08-14

    申请号:US10599704

    申请日:2005-04-01

    CPC分类号: A61K31/439

    摘要: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylquinuclidine derivative that inhibits pathogenic infectivity, including pharmaceutically acceptable salts

    摘要翻译: 本发明提供了预防或治疗哺乳动物(例如人)中的病理状况或症状的治疗方法,其中牵涉到病原体如逆转录病毒对哺乳动物细胞的感染性,并且希望抑制其感染性,包括给予 需要这种治疗的哺乳动物,有效量的抑制病原性感染性的苯甲酰奎宁环衍生物,包括药学上可接受的盐

    Neuroprotective benzoate and benzamide compounds
    10.
    发明申请
    Neuroprotective benzoate and benzamide compounds 审中-公开
    神经保护性苯甲酸酯和苯甲酰胺化合物

    公开(公告)号:US20060167108A1

    公开(公告)日:2006-07-27

    申请号:US11292781

    申请日:2005-12-02

    IPC分类号: A61K31/165 A61K31/16

    摘要: The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明提供在哺乳动物(例如人)中治疗至少一种神经障碍或疾病如阿尔茨海默病的症状的治疗方法,其中涉及哺乳动物细胞中β淀粉样肽和/或谷氨酸的病原体的毒性 并且期望抑制随后诱导的病理学途径,包括向需要这种治疗的哺乳动物施用有效量的N-芳基酰胺或(N-氨基烷基)苯甲酰胺,包括其药学上可接受的盐。